Uso de la PET-18F-FDG en pacientes con sospecha de recurrencia de cáncer diferenciado de tiroides por anticuerpos anti-tiroglobulina elevados y rastreo 131I negativo

Viedma, S. Sanz; Dorado, I. Borrego; Rodríguez, José Ramón; González, Elena Navarro; Albertino, R. Vázquez; López, Rosa Fernández; Martínez, Alejandro Rodríguez

doi:10.1016/j.remn.2010.10.012

Cited by 6 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remaining 10 full-text articles were assessed for eligibility and 1 article was excluded due to unavailability of sufficient numerical data (n = 9) for the calculation of sensitivity and specificity of F-18 FDG PET or PET/CT for the detection of recurrent and/or metastatic diseases in DTC patients with progressively and/or persistently elevated TgAb levels and negative RI-WBS. Finally, 9 studies were selected and were eligible for the systematic review and meta-analysis, and no additional studies were found screening the references of these articles (Chung et al 2002, Seo et al 2010, Bogsrud et al 2011, Kingpetch et al 2011, Viedma et al 2011, Ozkan et al 2012, Asa et al 2014, Qiu et al 2017. The characteristics of the included studies are presented in Table 1.…”

Section: Literature Search and Selection Of Studiesmentioning

confidence: 99%

“…Among those 9 studies included in the current review, 8 studies conducted patient-based analysis of F-18 FDG PET/CT (Chung et al 2002, Seo et al 2010, Bogsrud et al 2011, Kingpetch et al 2011, Ozkan et al 2012, Asa et al 2014, Qiu et al 2017. The other study conducted lesionbased analysis (Viedma et al 2011). There were a total of 515 patients in the included studies, and the age ranged from 17 to 82 years.…”

Section: Study Description Quality and Publication Biasmentioning

confidence: 99%

“…A total 50 patients were male, and 142 patients were female. The four studies did not report the number of male and female patients in their population (Seo et al 2010, Kingpetch et al 2011, Viedma et al 2011, Ozkan et al 2013. Of all 9 studies enrolled patients retrospectively.…”

Section: Study Description Quality and Publication Biasmentioning

confidence: 99%

“…Of all 9 studies enrolled patients retrospectively. Six studies used PET/CT (Seo et al 2010, Kingpetch et al 2011, Ozkan et al 2012, Asa et al 2014, Qiu et al 2017 and other studies (Chung et al 2002, Bogsrud et al 2011, Viedma et al 2011 used PET as imaging device in their studies. The principal characteristics of the 9 studies Figure 1 Flow chart of the search for eligible studies on the diagnostic performance of F-18 FDG PET or PET/CT for detection of recurrent and/or metastatic diseases in DTC patients with progressively and/or persistently elevated TgAb levels and negative RI-WBS.…”

Section: Study Description Quality and Publication Biasmentioning

confidence: 99%

See 3 more Smart Citations

Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab

Kim

Lee

Pak

et al. 2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

We aimed to explore the role of the diagnostic accuracy of F-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) for the detection of recurrent and/or metastatic diseases in differentiated thyroid cancer (DTC) patients with progressively and/or persistently elevated TgAb levels and negative radioactive iodine whole-body scan (RI-WBS) through a systematic review and meta-analysis. The MEDLINE, EMBASE and Cochrane Library database, from the earliest available date of indexing through June 30, 2017, were searched for studies evaluating the diagnostic performance of F-18 FDG PET/CT for the detection of recurrent and/or metastatic diseases in DTC patients with progressively and/or persistently elevated TgAb levels and negative RI-WBS. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-). Across 9 studies (515 patients), the pooled sensitivity for F-18 FDG PET/CT was 0.84 (95% CI; 0.77-0.89) a pooled specificity of 0.78 (95% CI; 0.67-0.86). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 3.8 (95% CI; 2.5-5.7) and negative likelihood ratio (LR-) of 0.21 (95% CI; 0.14-0.30). The pooled diagnostic odds ratio (DOR) was 18 (95% CI; 10-34). The area (AUC) under the hierarchical summary receiver-operating characteristic (HCROC) curve was 0.88 (95% CI: 0.85-0.90). F-18 FDG PET or PET/CT demonstrated moderate sensitivity and specificity for the detection of recurrent and/or metastatic diseases in DTC patients with progressively and/or persistently elevated TgAb levels and negative RI-WBS.

show abstract

Section: Literature Search and Selection Of Studiesmentioning

confidence: 99%

Section: Study Description Quality and Publication Biasmentioning

confidence: 99%

Section: Study Description Quality and Publication Biasmentioning

confidence: 99%

Section: Study Description Quality and Publication Biasmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab

Kim

Lee

Pak

et al. 2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…17 20022684.6%92.3%——88.4%Viedma et al . 18 201122100%62.5%50%100%72.7%Bogsrud et al . 19 20111583.3%100%100%71.4%70.6%Ozkan et al .…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Performance of 18F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative 131I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level

Qiu

Wei

Shen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Differentiated thyroid cancer (DTC) patients with negative serum thyroglobulin (Tg), negative 131I whole–body scintigraphy (131I-WBS) at first post-ablation and progressively increased TgAb level are a relatively rare entity in the follow-up after total thyroidectomy and radioactive iodine therapy. The value of 18F-FDG PET/CT in detecting the recurrence of disease in these patients has only been reported in a small case series. The goal of this study was to investigate the diagnostic accuracy of 18F-FDG PET/CT in detecting recurrent disease in these specific PTC patients and to identify risk factors for patients with positive 18F-FDG PET/CT results. Eighty-two PTC patients who had 18F-FDG PET/CT scans with negative Tg, negative 131I-WBS at first post-ablation and progressively increased TgAb levels were included. We found that the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-FDG PET/CT in this patient group were determined as 84%, 72%, 92%, 57% and 82%, respectively. 18F-FDG PET/CT scan had a good diagnostic performance and should be performed routinely in PTC patients with negative Tg, negative 131I-WBS at first postablation and progressively increased TgAb level, especially when span for progressively increased TgAb level ≥ 3 years and/or progressively increased TgAb value up to 150 IU/mL.

show abstract